Abstract:TMP195 is a highly profiled clinical candidate demonstrating class IIa histone deacetylase (HDAC) selective inhibition. Current preparation of TMP195 is limited to subgram-scale due to the requirement of tedious (post-)experimental procedures and the uses of hazardous reagents. To fulfill the unmet need for the bulky synthesis of TMP195 for the future clinical study, we have carried out its synthetic research. The present study provides a novel synthetic process suitable for the multigram-scale synthesis of TMP195 . Its overall yield has increased significantly from the literature to the present, with respective values of 9% and 45%. Notably, the proposed process is more efficient and facile, characterized by accelerated reaction rates from 40 h to within 19 h and a streamlined post-reaction column chromatography purification from five reactions to just one. Additionally, the proposed process is more environmentally friendly, featured by the solvent-free synthesis of key intermediate 4-(chloromethyl)-2-phenyloxazole and replacement of non-toxic cyanide source. This newly proposed synthetic process is highly stable and repeatable under 10 gramme scale counted by benzamide as starting material.

Development of a multigram synthetic process to clinical candidate TMP195, a class IIa histone deacetylase selective inhibitor

Development of Two Scalable Syntheses of 4-Amino-5-aminomethyl-2-methylpyrimidine: Key Intermediate for Vitamin B 1

Feasible Column Chromatography-Free, Multi-Gram Scale Synthetic Process of VH032 Amine, Which Could Enable Rapid PROTAC Library Construction.

Development of a Scalable Synthesis of Mevidalen (LY3154207), an Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor

A sub-milligram-synthesis protocol for in vitro screening of HDAC11 inhibitors.

Development of a Continuous Flow Process for the Efficient Preparation of Anti-Tuberculosis-Specific Drug TBAJ-876

New Method for Synthesis of Ezh2 Methyltransferase Inhibitor Gsk126

Development of a Concise Multikilogram Synthesis of LPA-1 Antagonist BMS-986020 Via a Tandem Borylation–Suzuki Procedure

Process Development of a Novel Azetidinyl Ketolide Antibiotic

Design and Synthesis of HDAC Inhibitors to Enhance the Therapeutic Effect of Diffuse Large B-cell Lymphoma by Improving Metabolic Stability and Pharmacokinetic Characteristics.

Development of a Cost-Efficient Process Toward a Key Synthetic Intermediate of the EZH2 Inhibitor PF-06821497

Process Development and GMP Production of a Conjugate Warhead: Auristatin F-HPA-Ala/TFA (XMT-1864/TFA)

Synthesis of STM2457, a selective small-molecule inhibitor of METTL3

Two Approaches to the Chemical Development and Large-Scale Preparation of a Pyrimidyl Tetrazole Intermediate

Process Development and Manufacture of the Core Starting Material of Adagrasib (MRTX849)

Synthesis and biological evaluation of ortho-phenyl phenylhydroxamic acids containing phenothiazine with improved selectivity for class IIa histone deacetylases

Process Development and Scale-Up of a Novel Atypical DAT Inhibitor ( S )-CE-123

Optimization and Development of a Scalable Palladium-Catalyzed C–H Activation Process for the Geometry-Selective Preparation of Kilograms of YLF466D, a Potent AMP-Activated Protein Kinase Activator

Synthesis of a 5-((Aryloxy)methyl)-3-(4-(trifluoromethyl)phenyl)[1,2,4]thiadiazole Derivative: A Promising PPARα,δ Agonist

Development of an Efficient and Scalable Biocatalytic Route to (1S,4r)-8-hydroxy-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl Propionate Via Enantioselective Enzymatic Desymmetrization of a Prochiral Diester

Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir